Boston Scientific Corporation $BSX Shares Bought by Atlatl Advisers LLC

Atlatl Advisers LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 4.2% during the 2nd quarter, Holdings Channel reports. The firm owned 6,313 shares of the medical equipment provider’s stock after purchasing an additional 254 shares during the period. Atlatl Advisers LLC’s holdings in Boston Scientific were worth $678,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of BSX. Vanguard Group Inc. increased its position in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after purchasing an additional 1,664,108 shares during the period. Swedbank AB increased its position in shares of Boston Scientific by 114.5% during the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after purchasing an additional 1,505,019 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares during the period. Finally, Ninety One UK Ltd increased its position in shares of Boston Scientific by 33.5% during the 2nd quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock valued at $552,755,000 after purchasing an additional 1,290,414 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BSX has been the topic of several research analyst reports. Barclays lifted their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Wells Fargo & Company raised their price objective on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average price target of $123.77.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 170,214 shares of company stock valued at $17,548,337 over the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $101.08 on Friday. The stock has a market cap of $149.78 billion, a PE ratio of 54.06, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The business has a fifty day simple moving average of $101.14 and a 200-day simple moving average of $102.08. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.Boston Scientific’s revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.